



RECEIVED

WDGP 1652

JUL 12 2000

box Seq

TECH CENTER 1600/2900

PATENT

ATTORNEY DOCKET NO. 07064/009001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Girish Sahni et al.

Art Unit: 1652

Serial No.: 09/471,349

Examiner: K. Kerr

Filed : December 23, 1999

Title : NOVEL CLOT-SPECIFIC STREPTOKINASE PROTEINS POSSESSING  
ALTERED PLASMINOGEN ACTIVATION CHARACTERISTICS AND A  
PROCESS FOR THE PREPARATION OF SAID PROTEINS

Box Sequence

Commissioner for Patents

Washington, DC 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE AND/OR AMINO ACID SEQUENCES

In response to the communication dated June 7, 2000,

Applicants submit herewith, a Sequence Listing in computer  
readable form as required by 37 CFR §1.821(e). In addition,  
Applicants submit a Sequence Listing as required under 37 CFR  
§1.821(c) and a statement under 37 CFR §1.821(f).

I hereby state that the submission, filed in accordance  
with 37 CFR §1.821(g), does not contain new matter.

No fees are believed due. However, please apply any  
fees or credit to Deposit Account No. 06-1050, referencing  
Attorney Docket No. 07064-009001.

Date: 7/8/00

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110-2804  
Telephone: 617/542-5070  
Facsimile: 617/542-8906

Respectfully submitted,

John W. Freeman

John W. Freeman  
Reg. No. 29,066


Date of Deposit July 7, 2000  
I hereby certify under 37 CFR 1.8(a) that this correspondence  
is being deposited with the United States Postal Service as  
first class mail with sufficient postage on the date indicated  
above and is addressed to the Commissioner for Patents,  
Washington, D.C. 20231

Toni M. Soosa

RECEIVED

JUL 12 2000

Application No.: 09/471,349



**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**



PATENT

ATTORNEY DOCKET NO. 07064/009001

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.: Girish Sahni et al.

Art Unit: 1652

Serial No.: 09/471,349

Examiner: K. Kerr

Filed : December 23, 1999

Title : NOVEL CLOT-SPECIFIC STREPTOKINASE PROTEINS POSSESSING  
ALTERED PLASMINOGEN ACTIVATION CHARACTERISTICS AND A  
PROCESS FOR THE PREPARATION OF SAID PROTEINS

Box Sequence

Commissioner for Patents  
Washington, DC 20231RECEIVED  
JUL 13 2000VERIFIED STATEMENT UNDER 37 CFR § 1.821 (f)

I, Maureen Ruttle, declare that I personally prepared the paper and the computer-readable copies of the Sequence Listing filed herewith in the above-entitled case and that the content of both is the same.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of The United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: July 7, 2000Maureen Ruttle  
Maureen RuttleFish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110-2804Telephone: 617/542-5070  
Facsimile: 617/542-8906

Date of Deposit

I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

July 7, 2000Tan M. Sausa  
Tan M. Sausa